Trials / Completed
CompletedNCT02547844
Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla
Open Randomized Study to Assess the Evolution of Plasma Lipid Profile by Lipidomic in Patients Infected With Human Immunodeficiency Virus (HIV-1) With Viral Suppression That Change Atripla® to Eviplera® Compared to Continue With Atripla®
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the lipidomic profile in patients with HIV-1 with viral suppression changing efavirenz + emtricitabine + tenofovir (Atripla) to rilpivirine + emtricitabine + tenofovir (Eviplera®) versus a group of patients that continue with Atripla®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | efavirenz + emtricitabina + tenofovir | |
| DRUG | rilpivirina + emtricitabina + tenofovir |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2016-10-01
- Completion
- 2016-10-01
- First posted
- 2015-09-11
- Last updated
- 2017-06-14
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02547844. Inclusion in this directory is not an endorsement.